Regarding CKD models, an increase in mortality has been observed in preclinical trials using a high-affinity blockade of FGF23 [62]; however, an increase in survival has been observed in end-stage CKD patients using calcimimetics as the inhibition of PTH production results in a modest reduction in FGF23 levels [168]. The gene discussed is PTH; the disease is chronic kidney disease.